Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAPHAEL E SZALAT

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1801394663
CMS profile
8953071
Location
BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$3,025.00

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,025.00 2

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Scientific Affairs, LLC $3,025.00 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAPHAEL E SZALAT

NPI 1801394663 · CMS profile ID 8953071

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1801394663?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAPHAEL E SZALAT, NPI 1801394663, CMS profile ID 8953071. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801394663?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RAPHAEL E SZALAT, NPI 1801394663, CMS profile ID 8953071. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801394663?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RAPHAEL E SZALAT, NPI 1801394663, CMS profile ID 8953071, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1801394663?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $3,025.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Scientific Affairs, LLC $1,375.0010/14/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078851450 CMS
Janssen Scientific Affairs, LLC $1,650.0002/21/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078851566 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $99.00 1
PY2022 $38.30 1
PY2023 $840.00 1
PY2024 $3,025.00 2
PY2025 $31.80 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $20,315.00 10
PY2025 Principal investigator $163,391.99 21
PY2024 Principal investigator $92,280.00 19
PY2023 Principal investigator $110,784.80 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $4,272.00 12/22/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide No dispute reported 06/30/2026 1175304449
Principal investigator 1 Janssen Research & Development, LLC $4,742.00 12/18/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy No dispute reported 06/30/2026 1175304328
Recipient Regeneron Pharmaceuticals, Inc. $4,650.00 12/09/2025 Covered Recipient Physician AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184123308
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $39,978.49 12/04/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma No dispute reported 06/30/2026 1236001693
Principal investigator 1 Janssen Research & Development, LLC $5,027.00 11/21/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy No dispute reported 06/30/2026 1175304456
Recipient Regeneron Pharmaceuticals, Inc. $3,350.00 11/11/2025 Covered Recipient Physician A PHASE 1 STUDY TO INVESTIGATE THE SAFETY AND PHARMACOKINETICS OF REGN2810 (ANTI-PD-1) IN JAPANESE PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 1184123306
Principal investigator 1 Janssen Research & Development, LLC $8,112.00 11/07/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide No dispute reported 06/30/2026 1175304573
Principal investigator 1 Janssen Research & Development, LLC $2,371.00 10/27/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy No dispute reported 06/30/2026 1175304469
Recipient Regeneron Pharmaceuticals, Inc. $3,290.00 10/07/2025 Covered Recipient Physician AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184123304
Principal investigator 1 Janssen Research & Development, LLC $4,742.00 10/03/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Receivedat Least 1 Prior Line of Therapy No dispute reported 06/30/2026 1175304603
Recipient Regeneron Pharmaceuticals, Inc. $4,700.00 09/09/2025 Covered Recipient Physician AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184123302
Principal investigator 1 Janssen Research & Development, LLC $22,003.00 08/21/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175304405
Recipient Regeneron Pharmaceuticals, Inc. $1,120.00 08/08/2025 Covered Recipient Physician AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184123300
Principal investigator 1 Janssen Research & Development, LLC $2,371.00 07/31/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175304530
Recipient Regeneron Pharmaceuticals, Inc. $1,725.00 07/01/2025 Covered Recipient Physician AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184123298
Principal investigator 1 Janssen Research & Development, LLC $4,742.00 06/30/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175304366
Principal investigator 1 Janssen Research & Development, LLC $4,272.00 06/02/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175304349
Principal investigator 1 Janssen Research & Development, LLC $2,134.00 05/26/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175304434
Recipient Regeneron Pharmaceuticals, Inc. $875.00 05/20/2025 Covered Recipient Physician AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184123296
Recipient Regeneron Pharmaceuticals, Inc. $150.00 05/06/2025 Covered Recipient Physician AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184123294
Principal investigator 1 Janssen Research & Development, LLC $12,343.00 05/01/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175304637
Recipient Regeneron Pharmaceuticals, Inc. $210.00 04/15/2025 Covered Recipient Physician AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184123292
Principal investigator 1 Janssen Research & Development, LLC $10,605.00 04/04/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175304418
Principal investigator 1 Janssen Research & Development, LLC $325.00 04/04/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175304629
Principal investigator 1 Janssen Research & Development, LLC $5,507.00 04/03/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175304397
Recipient Regeneron Pharmaceuticals, Inc. $245.00 03/04/2025 Covered Recipient Physician AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI- BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPD), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3) No dispute reported 06/30/2026 1184123290
Principal investigator 1 Janssen Research & Development, LLC $4,272.00 03/03/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther No dispute reported 06/30/2026 1175304463
Principal investigator 1 Janssen Research & Development, LLC $2,134.00 03/03/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175304522
Principal investigator 1 Janssen Research & Development, LLC $20,581.00 02/17/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175304619
Principal investigator 1 Janssen Research & Development, LLC $487.50 02/10/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175304547
Principal investigator 1 Janssen Research & Development, LLC $2,371.00 01/24/2025 Covered Recipient Teaching Hospital
Boston Medical Center
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone(DPd), in Participants With R No dispute reported 06/30/2026 1175304358